A Phase 3 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 12 in phase 3, and was the 18th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 31st largest by enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2012, is one of 23 in phase 3, and was the 27th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient population that closely resembles the clinical population seen in routine medical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have been treated with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
Drug: Fingolimod
Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity
Time frame: 28 weeks
Number (%) of Patients With AE of Special Interest Including Bradyarrhythmia, BP Increase, Liver Transaminase Elevations, Infections , Macula Oedema.
The incidence of events in special areas of safety interest (including bradyarrhythmias, BP increase, liver function, infections and macular oedema) were assessed by the nature and frequency of AE reporting. These areas of special interest have been identified and potential risks of fingolimod based on knowledge from clinical trials and post-marketing reporting.
Time frame: 4 months
| Milestone | Fingolimod 0.5 mg |
|---|---|
| Started | 162 |
| Completed | 151 |
| Not completed | 11 |
| Withdrew: Abnormal lab values | 4 |
| Withdrew: Abnormal test procedure result | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol violation | 1 |
The incidence of events in special areas of safety interest (including bradyarrhythmias, BP increase, liver function, infections and macular oedema) were assessed by the nature and frequency of AE reporting. These areas of special interest have been identified and potential risks of fingolimod based on knowledge from clinical trials and post-marketing reporting.
| Percent of Participants | Fingolimod 0.5 mg |
|---|---|
| Bradyarrhythmias | 8.6 |
| Blood pressure increase | 0.6 |
| Hypertension | 2.5 |
| Liver Transaminase evaluations | 3.7 |
| Infections | 28.4 |
| Macula Oedema | 0 |
Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity
| Participants | Fingolimod 0.5 mg |
|---|---|
| Adverse Events (AE) | 100 |
| Serious Adverse Event (SAE) | 12 |
| Deaths | 0 |
Collected over Weeks 2,8, 16 and end of study visit. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 0.5 mg | — | 12/162 (7.4%) | 63/162 (38.9%) |
| Event | Fingolimod 0.5 mg |
|---|---|
| Multiple sclerosis relapseNervous system disorders | 3/162 |
| GastroenteritisInfections and infestations | 2/162 |
| LeukopeniaBlood and lymphatic system disorders | 1/162 |
| Gastroenteritis viralInfections and infestations | 1/162 |
| Urinary tract infectionInfections and infestations | 1/162 |
| Fibrin D dimer increasedInvestigations | 1/162 |
| White blood cell count decreasedInvestigations | 1/162 |
| Optic neuritisNervous system disorders | 1/162 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/162 |
| HypertensionVascular disorders | 1/162 |
| Event | Fingolimod 0.5 mg |
|---|---|
| HeadacheNervous system disorders | 22/162 |
| LymphopeniaBlood and lymphatic system disorders | 17/162 |
| FatigueGeneral disorders | 10/162 |
| DiarrhoeaGastrointestinal disorders | 8/162 |
| Upper respiratory tract infectionInfections and infestations | 8/162 |
| BradycardiaCardiac disorders | 6/162 |
| NauseaGastrointestinal disorders | 5/162 |
| Back painMusculoskeletal and connective tissue disorders | 5/162 |
| DizzinessNervous system disorders | 5/162 |
| AnxietyPsychiatric disorders | 5/162 |
The Enrolled Set (ENR) included all patients who signed the informed consent and enrolled in study
| Age, Continuous(Years) | Fingolimod 0.5 mg |
|---|---|
| Mean | 37.3 ± 9.67 |
| Age, Customized(Participants) | Fingolimod 0.5 mg |
|---|---|
| <18 years | 0 |
| 18-30 years | 47 |
| 31-40 years | 60 |
| 41-55 years | 47 |
| 56-65 years | 8 |
| >65 years | 0 |
| Sex: Female, Male(Participants) | Fingolimod 0.5 mg |
|---|---|
| Female | 114 |
| Male | 48 |
The record gives a start of Feb 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod